Current challenges and controversies in drug-induced liver injury.

Drug- and herb-induced liver injury: Progress, current challenges and emerging signals of post-marketing risk. World J Hepatol (2015) 0.99

High-content assays for hepatotoxicity using induced pluripotent stem cell-derived cells. Assay Drug Dev Technol (2013) 0.95

Lessons from a BACE1 inhibitor trial: off-site but not off base. Alzheimers Dement (2014) 0.89

A comprehensive study of the association between drug hepatotoxicity and daily dose, liver metabolism, and lipophilicity using 975 oral medications. Oncotarget (2015) 0.86

Assessing liver injury associated with antimycotics: Concise literature review and clues from data mining of the FAERS database. World J Hepatol (2014) 0.82

Co-culture of Hepatocytes and Kupffer Cells as an In Vitro Model of Inflammation and Drug-Induced Hepatotoxicity. J Pharm Sci (2016) 0.80

Elucidating Differences in the Hepatotoxic Potential of Tolcapone and Entacapone With DILIsym(®), a Mechanistic Model of Drug-Induced Liver Injury. CPT Pharmacometrics Syst Pharmacol (2016) 0.77

The transformation in biomarker detection and management of drug-induced liver injury. Liver Int (2017) 0.75

Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts. Mol Cancer Ther (2004) 5.69

Causes, clinical features, and outcomes from a prospective study of drug-induced liver injury in the United States. Gastroenterology (2008) 5.45

Mechanisms of hepatotoxicity. Toxicol Sci (2002) 4.13

Atorvastatin reduces the ability of clopidogrel to inhibit platelet aggregation: a new drug-drug interaction. Circulation (2003) 4.00

c-Jun N-terminal kinase plays a major role in murine acetaminophen hepatotoxicity. Gastroenterology (2006) 3.76

Neutrophil depletion protects against murine acetaminophen hepatotoxicity. Hepatology (2006) 3.70

Aminotransferase elevations in healthy adults receiving 4 grams of acetaminophen daily: a randomized controlled trial. JAMA (2006) 3.49

Drug-Induced Liver Injury Network (DILIN) prospective study: rationale, design and conduct. Drug Saf (2009) 3.48

Betaine decreases hyperhomocysteinemia, endoplasmic reticulum stress, and liver injury in alcohol-fed mice. Gastroenterology (2003) 3.18

Role of JNK translocation to mitochondria leading to inhibition of mitochondria bioenergetics in acetaminophen-induced liver injury. J Biol Chem (2008) 3.08

Hepatitis C virus core protein inhibits microsomal triglyceride transfer protein activity and very low density lipoprotein secretion: a model of viral-related steatosis. FASEB J (2002) 3.06

The Ala16Val genetic dimorphism modulates the import of human manganese superoxide dismutase into rat liver mitochondria. Pharmacogenetics (2003) 2.87

Mitochondrial dysfunction in NASH: causes, consequences and possible means to prevent it. Mitochondrion (2006) 2.68

Clinical risk factors for portopulmonary hypertension. Hepatology (2008) 2.62

Peroxynitrite-induced mitochondrial and endonuclease-mediated nuclear DNA damage in acetaminophen hepatotoxicity. J Pharmacol Exp Ther (2005) 2.41

Identifying genetic risk factors for serious adverse drug reactions: current progress and challenges. Nat Rev Drug Discov (2007) 2.32

Innate immune system plays a critical role in determining the progression and severity of acetaminophen hepatotoxicity. Gastroenterology (2004) 2.26

Activation of the Nlrp3 inflammasome in infiltrating macrophages by endocannabinoids mediates beta cell loss in type 2 diabetes. Nat Med (2013) 2.19

Outcome of acute idiosyncratic drug-induced liver injury: Long-term follow-up in a hepatotoxicity registry. Hepatology (2006) 2.12

Renal biomarker qualification submission: a dialog between the FDA-EMEA and Predictive Safety Testing Consortium. Nat Biotechnol (2010) 2.06

Susceptibility to amoxicillin-clavulanate-induced liver injury is influenced by multiple HLA class I and II alleles. Gastroenterology (2011) 2.01

Drug-induced liver injury. Drug Saf (2007) 1.99

Contribution of hepatic cytochrome P450 3A4 metabolic activity to the phenomenon of clopidogrel resistance. Circulation (2004) 1.94

Identification and characterization of infiltrating macrophages in acetaminophen-induced liver injury. J Leukoc Biol (2008) 1.93

Predominant role of sterol response element binding proteins (SREBP) lipogenic pathways in hepatic steatosis in the murine intragastric ethanol feeding model. J Hepatol (2006) 1.89

Hepatic histological findings in suspected drug-induced liver injury: systematic evaluation and clinical associations. Hepatology (2013) 1.81

Inhibition of microsomal triglyceride transfer protein: another mechanism for drug-induced steatosis in mice. Hepatology (2003) 1.79

Steroid and xenobiotic receptor and vitamin D receptor crosstalk mediates CYP24 expression and drug-induced osteomalacia. J Clin Invest (2006) 1.75

Role of the Kupffer cell in mediating hepatic toxicity and carcinogenesis. Toxicol Sci (2006) 1.75

Sensitivity of the 2-oxoglutarate carrier to alcohol intake contributes to mitochondrial glutathione depletion. Hepatology (2003) 1.72

Hepatic but not intestinal CYP3A4 displays dose-dependent induction by efavirenz in humans. Clin Pharmacol Ther (2002) 1.68

Hyperhomocysteinemia, endoplasmic reticulum stress, and alcoholic liver injury. World J Gastroenterol (2004) 1.68

Mechanisms of drug-induced liver injury. AAPS J (2006) 1.65

Gene expression in two hepatic cell lines, cultured primary hepatocytes, and liver slices compared to the in vivo liver gene expression in rats: possible implications for toxicogenomics use of in vitro systems. Toxicol Sci (2003) 1.64

Effect of glutathione depletion on sites and topology of superoxide and hydrogen peroxide production in mitochondria. Mol Pharmacol (2003) 1.62

Mechanisms of liver injury. III. Role of glutathione redox status in liver injury. Am J Physiol Gastrointest Liver Physiol (2006) 1.62

ASMase is required for chronic alcohol induced hepatic endoplasmic reticulum stress and mitochondrial cholesterol loading. J Hepatol (2013) 1.61

Mouse population-guided resequencing reveals that variants in CD44 contribute to acetaminophen-induced liver injury in humans. Genome Res (2009) 1.60

ER stress: can the liver cope? J Hepatol (2006) 1.58

c-Jun N-terminal kinase (JNK)-dependent acute liver injury from acetaminophen or tumor necrosis factor (TNF) requires mitochondrial Sab protein expression in mice. J Biol Chem (2011) 1.57

Glutathione in liver diseases and hepatotoxicity. Mol Aspects Med (2008) 1.55

Serum alanine aminotransferase in skeletal muscle diseases. Hepatology (2005) 1.54

Hepatic mitochondrial glutathione: transport and role in disease and toxicity. Toxicol Appl Pharmacol (2005) 1.54

Reliability of the Roussel Uclaf Causality Assessment Method for assessing causality in drug-induced liver injury. Hepatology (2008) 1.53

Acetaminophen hepatoxicity: what do we know, what don't we know, and what do we do next? Hepatology (2004) 1.51

Impact of hepatopulmonary syndrome on quality of life and survival in liver transplant candidates. Gastroenterology (2008) 1.50

The contribution of endoplasmic reticulum stress to liver diseases. Hepatology (2011) 1.50

Role of CHOP in hepatic apoptosis in the murine model of intragastric ethanol feeding. Alcohol Clin Exp Res (2005) 1.49

Role of S-adenosylmethionine, folate, and betaine in the treatment of alcoholic liver disease: summary of a symposium. Am J Clin Nutr (2007) 1.49

Mechanisms of immune-mediated liver injury. Toxicol Sci (2010) 1.48

The manganese superoxide dismutase Ala16Val dimorphism modulates both mitochondrial import and mRNA stability. Pharmacogenet Genomics (2005) 1.45

Genetic risk factors for portopulmonary hypertension in patients with advanced liver disease. Am J Respir Crit Care Med (2009) 1.44

The role of damage associated molecular pattern molecules in acetaminophen-induced liver injury in mice. Toxicol Lett (2009) 1.42

Mechanism of T cell tolerance induction by murine hepatic Kupffer cells. Hepatology (2008) 1.41

Pharmacokinetics of anti-influenza prodrug oseltamivir in children aged 1-5 years. Eur J Clin Pharmacol (2003) 1.39

Immune-mediated drug-induced liver disease. Clin Liver Dis (2002) 1.38

Regulation of mitochondrial glutathione redox status and protein glutathionylation by respiratory substrates. J Biol Chem (2010) 1.37

Variation in oral clearance of saquinavir is predicted by CYP3A5*1 genotype but not by enterocyte content of cytochrome P450 3A5. Clin Pharmacol Ther (2005) 1.35

Impaired adaptive resynthesis and prolonged depletion of hepatic mitochondrial DNA after repeated alcohol binges in mice. Gastroenterology (2002) 1.35

Phenotypic characterization of idiosyncratic drug-induced liver injury: the influence of age and sex. Hepatology (2009) 1.35

Role of innate immunity in acetaminophen-induced hepatotoxicity. Expert Opin Drug Metab Toxicol (2006) 1.35

Drug-induced liver injury through mitochondrial dysfunction: mechanisms and detection during preclinical safety studies. Fundam Clin Pharmacol (2008) 1.34

Intestinal and hepatic CYP3A4 catalyze hydroxylation of 1alpha,25-dihydroxyvitamin D(3): implications for drug-induced osteomalacia. Mol Pharmacol (2005) 1.33

Role of TNF-alpha in ethanol-induced hyperhomocysteinemia and murine alcoholic liver injury. Hepatology (2004) 1.31

Common allelic variants of cytochrome P4503A4 and their prevalence in different populations. Pharmacogenetics (2002) 1.30

A long-term three dimensional liver co-culture system for improved prediction of clinically relevant drug-induced hepatotoxicity. Toxicol Appl Pharmacol (2013) 1.25

Liver-specific loss of glucose-regulated protein 78 perturbs the unfolded protein response and exacerbates a spectrum of liver diseases in mice. Hepatology (2011) 1.23

Differential inhibition of rat and human Na+-dependent taurocholate cotransporting polypeptide (NTCP/SLC10A1)by bosentan: a mechanism for species differences in hepatotoxicity. J Pharmacol Exp Ther (2007) 1.22

Limited contribution of common genetic variants to risk for liver injury due to a variety of drugs. Pharmacogenet Genomics (2012) 1.21

Are patients with elevated liver tests at increased risk of drug-induced liver injury? Gastroenterology (2004) 1.21

Silencing glycogen synthase kinase-3beta inhibits acetaminophen hepatotoxicity and attenuates JNK activation and loss of glutamate cysteine ligase and myeloid cell leukemia sequence 1. J Biol Chem (2010) 1.20

NOX family NADPH oxidases in liver and in pancreatic islets: a role in the metabolic syndrome and diabetes? Biochem Soc Trans (2008) 1.20

Interlaboratory evaluation of rat hepatic gene expression changes induced by methapyrilene. Environ Health Perspect (2004) 1.19

Mechanisms for sensitization to TNF-induced apoptosis by acute glutathione depletion in murine hepatocytes. Hepatology (2003) 1.19

Biomarker discovery by imaging mass spectrometry: transthyretin is a biomarker for gentamicin-induced nephrotoxicity in rat. Mol Cell Proteomics (2006) 1.19

Role of neutrophils in a mouse model of halothane-induced liver injury. Hepatology (2006) 1.19

Redox regulation of tumor necrosis factor signaling. Antioxid Redox Signal (2009) 1.18

The Environmental Polymorphisms Registry: a DNA resource to study genetic susceptibility loci. Hum Genet (2008) 1.18

Current concepts and controversies in the treatment of alcoholic hepatitis. World J Gastroenterol (2006) 1.17

Signal transduction pathways involved in drug-induced liver injury. Handb Exp Pharmacol (2010) 1.16

Discriminating different classes of toxicants by transcript profiling. Environ Health Perspect (2004) 1.16

Mechanisms of drug-induced liver disease. Clin Liver Dis (2007) 1.15

Metabolomics in toxicology: preclinical and clinical applications. Toxicol Sci (2010) 1.14

Acetaldehyde impairs mitochondrial glutathione transport in HepG2 cells through endoplasmic reticulum stress. Gastroenterology (2003) 1.14

Minireview: Challenges and opportunities in development of PPAR agonists. Mol Endocrinol (2014) 1.13

Reduced glutathione depletion causes necrosis and sensitization to tumor necrosis factor-alpha-induced apoptosis in cultured mouse hepatocytes. Hepatology (2002) 1.13

Marked elevation in serum transaminases: an atypical presentation of choledocholithiasis. Am J Gastroenterol (2005) 1.12

A furanocoumarin-free grapefruit juice establishes furanocoumarins as the mediators of the grapefruit juice-felodipine interaction. Am J Clin Nutr (2006) 1.12

CYP3A5 genotype predicts renal CYP3A activity and blood pressure in healthy adults. J Appl Physiol (1985) (2003) 1.11

Hydrogen peroxide and redox modulation sensitize primary mouse hepatocytes to TNF-induced apoptosis. Free Radic Biol Med (2006) 1.11

Mitochondrial glutathione: features, regulation and role in disease. Biochim Biophys Acta (2012) 1.11

Growth hormone secretion pattern is an independent regulator of growth hormone actions in humans. Am J Physiol Endocrinol Metab (2002) 1.10

Quantitative histological assessment of xenobiotic-induced liver enzyme induction and pituitary-thyroid axis stimulation in rats using whole-slide automated image analysis. J Histochem Cytochem (2013) 1.10

Mechanism of staurosporine-induced apoptosis in murine hepatocytes. Am J Physiol Gastrointest Liver Physiol (2002) 1.10

Polymerase γ gene POLG determines the risk of sodium valproate-induced liver toxicity. Hepatology (2010) 1.08

Differences in betaine-homocysteine methyltransferase expression, endoplasmic reticulum stress response, and liver injury between alcohol-fed mice and rats. Hepatology (2010) 1.08

Regulation of drug-induced liver injury by signal transduction pathways: critical role of mitochondria. Trends Pharmacol Sci (2013) 1.07

MDR1 genotype is associated with hepatic cytochrome P450 3A4 basal and induction phenotype. Clin Pharmacol Ther (2006) 1.06

Prostaglandin I(2) and E(2) mediate the protective effects of cyclooxygenase-2 in a mouse model of immune-mediated liver injury. Hepatology (2007) 1.05

Mechanisms of protection by the betaine-homocysteine methyltransferase/betaine system in HepG2 cells and primary mouse hepatocytes. Hepatology (2007) 1.05